This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 1975;231(6):583-608.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

1. INTRODUCTION

In a report that was published as a supplement to the November 1970 issue of Diabetes, the University Group Diabetes Program (UGDP) concluded that in patients with adult-onset diabetes, "tolbutamide and diet may be less effective [in prolonging life] than diet alone... at least insofar as cardiovascular mortality is concerned."^1,2 Of the subjects treated with tolbutamide, 12.7% died from cardiovascular causes, as compared with 6.2% or fewer in the other treatment groups. As a result of these findings, the Food and Drug Administration (FDA) recommended that tolbutamide should be used only in patients who had adult-onset, stable diabetes that could not be controlled by diet alone, and who, for some good reason, could not be treated with insulin.

The findings of the UGDP and the action of the FDA had a dramatic impact. Tolbutamide had been in general use in the treatment of diabetes since about 1956 . . . [Full Text PDF of this Article]

Footnotes
Reprint requests to Room 9A-52, Bldg 31, National Institutes of Health, Bethesda, MD 20014 (Mr. Francis L. Mills).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?